EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Summary

This phase Ib/II trial studies the side effects and best dose of EMB-01 when given together with osimertinib in patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (advanced or metastatic) and has progressed on standard treatment. EMB-01 and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth in this type of cancer. EMB-01 in combination with osimertinib may work better in treating patients with EGFR-mutant advanced non-small cell lung cancer.

Timeline

Start

2023-06

Primary completion

2024-07

Completion

2024-12

Drugs

Indications